A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Amgen Inc stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 40,879 shares of AMGN stock, worth $13 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
40,879
Previous 9,055 351.45%
Holding current value
$13 Million
Previous $2.57 Million 396.19%
% of portfolio
0.57%
Previous 0.36%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

BUY
$262.75 - $319.31 $8.36 Million - $10.2 Million
31,824 Added 351.45%
40,879 $12.8 Million
Q1 2024

Apr 11, 2024

BUY
$268.87 - $324.56 $2.43 Million - $2.94 Million
9,055 New
9,055 $2.57 Million
Q3 2023

Oct 06, 2023

BUY
$218.65 - $271.46 $1,967 - $2,443
9 Added 0.14%
6,477 $1.74 Million
Q1 2023

Apr 05, 2023

BUY
$225.79 - $275.2 $7,225 - $8,806
32 Added 0.5%
6,468 $1.56 Million
Q4 2022

Jan 10, 2023

SELL
$229.03 - $291.01 $60,005 - $76,244
-262 Reduced 3.91%
6,436 $0
Q3 2022

Oct 11, 2022

SELL
$224.46 - $253.15 $448 - $506
-2 Reduced 0.03%
6,698 $1.51 Million
Q2 2022

Jul 06, 2022

BUY
$230.71 - $256.74 $461 - $513
2 Added 0.03%
6,700 $1.63 Million
Q1 2022

Apr 26, 2022

BUY
$219.27 - $242.57 $1.47 Million - $1.62 Million
6,698 New
6,698 $1.62 Million
Q1 2022

Apr 11, 2022

SELL
$219.27 - $242.57 $1.47 Million - $1.62 Million
-6,689 Closed
0 $0
Q2 2021

Jul 12, 2021

BUY
$233.58 - $259.14 $23,358 - $25,914
100 Added 1.52%
6,689 $1.63 Million
Q4 2020

Jan 11, 2021

BUY
$216.38 - $257.67 $21,638 - $25,767
100 Added 1.54%
6,589 $1.52 Million
Q2 2020

Jul 07, 2020

BUY
$197.81 - $242.74 $1.28 Million - $1.58 Million
6,489 New
6,489 $1.53 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $170B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Wiley Bros. Aintree Capital, LLC Portfolio

Follow Wiley Bros. Aintree Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wiley Bros. Aintree Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wiley Bros. Aintree Capital, LLC with notifications on news.